UNSPSC 51111606: Hydroxycarbamide or hydroxyurea

This classification denotes a ribonucleotide reductase inhibitor and miscellaneous antimetabolite with the molecular formula CH4N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X6Q56QN5QC, chemically known as urea, n-hydroxy- but generally known as hydroxycarbamide, which bears US NIH Compound Identifier 3657. European Medicines Agency schedules Hydroxycarbamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08076MIG.

UNSPSC 51111606 Hydroxycarbamide or hydroxyurea, a Commodity code, covers the procurement of this specific pharmaceutical product by state and local health agencies. State and local governments buy hydroxycarbamide primarily through state health and human services departments managing Medicaid, employee health plans, and other public health programs. The procurement activity under this code reflects the broader shift toward direct-to-manufacturer pharmaceutical sourcing models, where health agencies negotiate pricing and supply arrangements outside traditional pharmacy benefit manager (PBM) and group purchasing organization (GPO) channels. State health systems use this code to acquire hydroxycarbamide for patient populations covered under public insurance programs, seeking cost management and supply-chain efficiency improvements through negotiated net pricing and outcomes-based contracting arrangements.

Texas Health and Human Services Commission posted Request for Information (RFI) HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI seeks vendor experience with direct contracting for self-insured employers and government health plans within the past two years, flexibility to negotiate contracts using negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. This exploratory procurement phase precedes formal solicitation with established financial and temporal parameters. No award value, budget range, or timeline for subsequent RFP issuance is identified in current materials; the state is gathering foundational market intelligence to inform future procurement strategy and contracting approach before committing to specific contract amounts or durations.